IN BRIEF: CRISM Therapeutics gets European patent for tumour therapy
19th Dec 2024 08:32
CRISM Therapeutics Corp - Surrey-headquartered pharmaceutical firm - Granted a European patent for its lead product ChemoSeed by the European Patent Office. This covers the manufacturing process for the preparation of chemotherapeutic drug implants and their use in therapy, particularly in treating brain tumours such as high grade glioma. ChemoSeed facilitates the local delivery of irinotecan directly to the brain tumour resection site, which allows the delivery of larger doses and reduces systemic concentrations. This alleviates traditional side effects for the patient. Read More